MUMBAI, India, Oct. 26 -- Intellectual Property India has published a patent application (202611112825 A) filed by Noida Institute Of Engineering And Technology Pharmacy Institute on September 21, 2026, for Optimized Resveratrol–sulforaphane Microemulsion Gel Enhancing Dermatokinetics For Synergistic Topical Breast Cancer Therapy.
Inventors include Dr Swarupanjali Padhi; and Dr. Monika.
The application for the patent was published on October 23, 2026, under issue no. 43/2026.
Abstract: The present invention relates to an optimized topical microemulsion-based gel formulation comprising a synergistic combination of resveratrol derived from Vitis vinifera and sulforaphane derived from Brassica oleracea var. italica, co-loaded in an oil-in-water microemulsion for localized breast cancer therapy. The microemulsion employs Capmul MCM C8, Transcutol P, and Cremophor ELP at 3:1 surfactant-to-co-surfactant ratio, optimized by Box-Behnken Design achieving droplet size below 200 nanometers and polydispersity index below 0.2. Incorporated into one percent Carbopol 934 gel, the formulation provides sustained 24-hour Higuchi diffusion-controlled release with drug loading of 0.5 milligrams per gram per active agent. Synergistic cytotoxicity against MCF-7 cells with combination index of 0.42 targets complementary NF-kB/PI3K/Akt and Nrf2/HDAC pathways. In vivo DMBA-induced breast tumor model demonstrates 67.4 percent tumor reduction. HET-CAM assay confirms non-irritancy. Confocal microscopy confirms penetra
Disclaimer: Curated by HT Syndication.
